Se connecter

Bibliographies thématiques / Antineoplastic agents / Articles de revues

Pour voir les autres types de publications sur ce sujet consultez le lien suivant : Antineoplastic agents.

Articles de revues sur le sujet « Antineoplastic agents »

Auteur : Grafiati

Publié le 4 juin 2021

Mis à jour le 25 juillet 2025

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les 50 meilleurs articles de revues pour votre recherche sur le sujet « Antineoplastic agents ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Parcourez les articles de revues sur diverses disciplines et organisez correctement votre bibliographie.

1

Carlson, Patricia A. "Antineoplastic agents." Critical Care Nursing Quarterly 18, no. 4 (1996): 1–15. http://dx.doi.org/10.1097/00002727-199602000-00002.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

2

Menta, Ernesto, and Manlio Palumbo. "Novel antineoplastic agents." Expert Opinion on Therapeutic Patents 7, no. 12 (1997): 1401–26. http://dx.doi.org/10.1517/13543776.7.12.1401.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

3

Menta, Ernesto, and Manlio Palumbo. "Antineoplastic agents 1998." Expert Opinion on Therapeutic Patents 8, no. 12 (1998): 1627–72. http://dx.doi.org/10.1517/13543776.8.12.1627.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

4

Pettit, G. R., Y. Kamano, R. Aoyagi, et al. "Antineoplastic agents 100." Tetrahedron 41, no. 6 (1985): 985–94. http://dx.doi.org/10.1016/s0040-4020(01)96466-x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

5

Bukowski, Ronald M. "Novel antineoplastic agents." Current Oncology Reports 2, no. 1 (2000): 9–10. http://dx.doi.org/10.1007/s11912-000-0004-1.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

6

Hong, Samuel J., Edward C. Li, Linda M. Matusiak, and Glen T. Schumock. "Spending on Antineoplastic Agents in the United States, 2011 to 2016." Journal of Oncology Practice 14, no. 11 (2018): e683-e691. http://dx.doi.org/10.1200/jop.18.00069.

Texte intégral

Résumé :

Purpose: Recent cancer drug approvals are lauded as being more effective with relatively fewer adverse effects, but these treatments come with a great cost to the US health care system. There is little information on recent trends in actual antineoplastic expenditures representative of the whole US health care system or by sector. Therefore, the objective of this study was to describe antineoplastic expenditures in the United States by year and sector. Methods: This was a retrospective, cross-sectional study of IQVIA (formerly QuintilesIMS) National Sales Perspective data for the period of Jan

Styles APA, Harvard, Vancouver, ISO, etc.

7

DOLL, DONALD C., Q. SCOT RINGENBERG, and JOHN W. YARBRO. "Antineoplastic Agents and Pregnancy." Obstetrical & Gynecological Survey 45, no. 6 (1990): 376. http://dx.doi.org/10.1097/00006254-199006000-00008.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

8

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 605. Isoquinstatins." Journal of Natural Products 81, no. 3 (2017): 451–57. http://dx.doi.org/10.1021/acs.jnatprod.7b00352.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

9

Hussain, M. A. ha, A. N. toinette J. Wozniak, and M. A. rk B. Edelstein. "Neurotoxicity of antineoplastic agents." Critical Reviews in Oncology/Hematology 14, no. 1 (1993): 61–75. http://dx.doi.org/10.1016/1040-8428(93)90006-p.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

10

Castells, M. "Hypersensitivity to Antineoplastic Agents." Current Pharmaceutical Design 14, no. 27 (2008): 2892–901. http://dx.doi.org/10.2174/138161208786369803.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

11

Fernandez, F. "Psychotoxicity from antineoplastic agents." Journal of Clinical Oncology 5, no. 2 (1987): 319–20. http://dx.doi.org/10.1200/jco.1987.5.2.319.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

12

McNabb, Lorna, Eva Metrot, Micaela Ferrington, et al. "Assessment of patient perceptions of counselling on oral antineoplastic agents by a dedicated cancer services pharmacist in an outpatient cancer clinic." PLOS ONE 19, no. 6 (2024): e0304011. http://dx.doi.org/10.1371/journal.pone.0304011.

Texte intégral

Résumé :

Background Oral antineoplastic agents have caused a paradigm shift in cancer treatment, however, they produce many unique challenges. Although oral antineoplastics can have complex administration regimes, low adherence rates and high possibilities of drug-drug interactions, they are administered unsupervised at home. Cancer services pharmacists have the required skillsets to improve patient outcomes associated with oral antineoplastic treatment by increasing patient health literacy, improving concordance and optimising administration protocols. Aim To evaluate patients’ perceptions, experience

Styles APA, Harvard, Vancouver, ISO, etc.

13

Melamed, Andra J., and Michael L. Kleinberg. "Handling Considerations for Cancer Chemotherapeutic Agents." Drug Intelligence & Clinical Pharmacy 22, no. 3 (1988): 247–51. http://dx.doi.org/10.1177/106002808802200317.

Texte intégral

Résumé :

Since the introduction of antineoplastic agents in the 1940s, there have been reports of the effects of these agents on workers who have had prolonged contact with them. The Regional Oncology Drug Information Center (RODIC) at Memorial Sloan-Kettering Cancer Center receives numerous inquiries nationwide regarding our policies and procedures for handling antineoplastic agents. In August 1987, RODIC conducted a computerized literature search on the handling of antineoplastic agents and the risks to hospital employees coming in contact with these agents. We used the MEDLINE system from 1966 to th

Styles APA, Harvard, Vancouver, ISO, etc.

14

Yamashiro, Yoshiko, Yoshikazu Fukuoka, Akira Yotsuji, Takashi Yasuda, Isamu Saikawa, and Yasushi Ueda. "Interactions of antimicrobial agents and antineoplastic agents." Journal of Antimicrobial Chemotherapy 18, no. 6 (1986): 703–8. http://dx.doi.org/10.1093/jac/18.6.703.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

15

Garcia, Gwenalyn, and Jean Paul Atallah. "Antineoplastic agents and thrombotic microangiopathy." Journal of Oncology Pharmacy Practice 23, no. 2 (2016): 135–42. http://dx.doi.org/10.1177/1078155216628324.

Texte intégral

Résumé :

Thrombotic microangiopathy is an uncommon but reported adverse effect of a variety of antineoplastic drugs, including chemotherapy agents such as mitomycin C and gemcitabine, and newer targeted agents such as the vascular endothelial growth factor inhibitors. We present a review of thrombotic microangiopathy associated with antineoplastic agents and its implications in current cancer therapy.

Styles APA, Harvard, Vancouver, ISO, etc.

16

Sutton, Karen, Tara B. Sanft, Tish M. Knobf, and Izuchukwu K. Ibe. "Musculoskeletal Effects of Antineoplastic Agents." Journal of the American Academy of Orthopaedic Surgeons 27, no. 22 (2019): 834–39. http://dx.doi.org/10.5435/jaaos-d-17-00713.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

17

PATTERSON, WILLIAM B. "Occupational Hazard from Antineoplastic Agents." Annals of Internal Medicine 103, no. 6_Part_1 (1985): 965. http://dx.doi.org/10.7326/0003-4819-103-6-965_2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

18

Graeve, Catherine Utecht, Patricia Marie McGovern, Bruce Alexander, Timothy Church, Andrew Ryan, and Martha Polovich. "Occupational Exposure to Antineoplastic Agents." Workplace Health & Safety 65, no. 1 (2016): 9–20. http://dx.doi.org/10.1177/2165079916662660.

Texte intégral

Résumé :

Approximately 8 million health care workers are unnecessarily exposed to highly toxic drugs used to treat cancer; antineoplastic drugs can contribute to negative health effects for these workers. The drugs have been detected in the urine of workers and on the floors and counters of worksites. Safety precautions that could reduce the risk of exposure are underutilized. This cross-sectional study of 163 oncology health care workers used a survey to measure workplace and individual factors, and environmental sampling to measure surface contamination. The study objective was to identify potential

Styles APA, Harvard, Vancouver, ISO, etc.

19

Bozkurt, Kürşat A., Burak Uzel, Canan Akman, Mustafa Özgüroğlu, and Nil Molinas Mandel. "Intrathoracic Extravasation of Antineoplastic Agents." American Journal of Clinical Oncology 26, no. 2 (2003): 121–23. http://dx.doi.org/10.1097/00000421-200304000-00003.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

20

Shahab, Nasir, Syed Haider, and Donald C. Doll. "Vascular Toxicity of Antineoplastic Agents." Seminars in Oncology 33, no. 1 (2006): 121–38. http://dx.doi.org/10.1053/j.seminoncol.2005.11.006.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

21

Fortner, Clarence L., and Paul J. Vilk. "Aspects of Investigational Antineoplastic Agents." Journal of Pharmacy Practice 4, no. 1 (1991): 64–71. http://dx.doi.org/10.1177/089719009100400107.

Texte intégral

Résumé :

Investigational drugs are regulated by the Food and Drug Administration (FDA) and are not available for widespread patient use. They are screened and evaluated extensively before they are administered to humans in clinical trials. The clinical development process is divided into three phases: phase I, II, and III. Protocols for the investigational agent in each of these phases must be approved by an institutional review board and the patient must be informed of the risks of the study and sign an informed consent document. Once adequate clinical data are collected and analyzed, the information

Styles APA, Harvard, Vancouver, ISO, etc.

22

Chitambar, Christopher R. "Gallium compounds as antineoplastic agents." Current Opinion in Oncology 16, no. 6 (2004): 547–52. http://dx.doi.org/10.1097/01.cco.0000142071.22226.d2.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

23

Hamnvik, O. P. R., P. R. Larsen, and E. Marqusee. "Thyroid Dysfunction from Antineoplastic Agents." JNCI Journal of the National Cancer Institute 103, no. 21 (2011): 1572–87. http://dx.doi.org/10.1093/jnci/djr373.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

24

Grangé, Steven, and Paul Coppo. "Thrombotic microangiopathies and antineoplastic agents." Néphrologie & Thérapeutique 13 (April 2017): S109—S113. http://dx.doi.org/10.1016/j.nephro.2017.01.016.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

25

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 606. The Betulastatins." Journal of Natural Products 81, no. 3 (2018): 458–64. http://dx.doi.org/10.1021/acs.jnatprod.7b00536.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

26

Pettit, George R., Noeleen Melody, and Jean-Charles Chapuis. "Antineoplastic Agents. 607. Emetine Auristatins." Journal of Natural Products 83, no. 5 (2020): 1571–76. http://dx.doi.org/10.1021/acs.jnatprod.0c00031.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

27

Pettit, G. R., S. B. Singh, A. Goswami, and R. A. Nieman. "Antineoplastic agents 157. Quassia kerstingII1." Tetrahedron 44, no. 11 (1988): 3349–54. http://dx.doi.org/10.1016/s0040-4020(01)85969-x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

28

Pettit, George R., Venkatswamy Gaddamidi, Delbert L. Herald, et al. "Antineoplastic Agents, 120. Pancratium littorale." Journal of Natural Products 49, no. 6 (1986): 995–1002. http://dx.doi.org/10.1021/np50048a005.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

29

Pettit, George R., Gordon M. Cragg, Sheo Bux Singh, James A. Duke, and Dennis L. Doubek. "Antineoplastic Agents, 162. Zephyranthes candida." Journal of Natural Products 53, no. 1 (1990): 176–78. http://dx.doi.org/10.1021/np50067a026.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

30

Rogers, Bonnie. "Antineoplastic Agents Action and Toxicities." AAOHN Journal 34, no. 11 (1986): 530–38. http://dx.doi.org/10.1177/216507998603401104.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

31

Bodet, C. A., J. H. Jorgensen, and D. J. Drutz. "Antibacterial activities of antineoplastic agents." Antimicrobial Agents and Chemotherapy 28, no. 3 (1985): 437–39. http://dx.doi.org/10.1128/aac.28.3.437.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

32

Pettit, George R., Noeleen Melody, Michael Simpson, Michael Thompson, Delbert L. Herald, and John C. Knight. "Antineoplastic Agents 500. Narcistatin†,1." Journal of Natural Products 66, no. 1 (2003): 92–96. http://dx.doi.org/10.1021/np020225i.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

33

Bozkurt, Kürşat A., Burak Uzel, Canan Akman, Mustafa Özgüroğlu, and Nil Molinas Mandel. "Intrathoracic Extravasation of Antineoplastic Agents." American Journal of Clinical Oncology 26, no. 2 (2003): 121–23. http://dx.doi.org/10.1097/01.coc.0000017088.74592.96.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

34

Borch, Richard F., and Thomas J. Montine. "Renal toxicity of antineoplastic agents." Toxicology Letters 53, no. 1-2 (1990): 93–96. http://dx.doi.org/10.1016/0378-4274(90)90100-z.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

35

Weiss, Raymond B., and James R. Baker. "Hypersensitivity reactions from antineoplastic agents." Cancer and Metastasis Reviews 6, no. 3 (1987): 413–32. http://dx.doi.org/10.1007/bf00144273.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

36

Hall, Amy L., Paul A. Demers, George Astrakianakis, Calvin Ge, and Cheryl E. Peters. "Estimating National-Level Exposure to Antineoplastic Agents in the Workplace: CAREX Canada Findings and Future Research Needs." Annals of Work Exposures and Health 61, no. 6 (2017): 656–58. http://dx.doi.org/10.1093/annweh/wxx042.

Texte intégral

Résumé :

AbstractObjectives:Occupational exposure to antineoplastic agents occurs in various environments and is associated with increased cancer risk and adverse reproductive outcomes. National-level information describing the location and extent of occupational exposure to antineoplastic agents is unavailable in Canada and most other countries. CAREX Canada aimed to estimate the prevalence and relative levels of occupational exposures to antineoplastic agents across work setting, occupation, and sex.Methods:‘Exposure’ was defined as any potential for worker contact with antineoplastic agents. Baselin

Styles APA, Harvard, Vancouver, ISO, etc.

37

Hamazaki, Risa, and Yoshihiro Uesawa. "Characterization of Antineoplastic Agents Inducing Taste and Smell Disorders Using the FAERS Database." Pharmaceuticals 17, no. 9 (2024): 1116. http://dx.doi.org/10.3390/ph17091116.

Texte intégral

Résumé :

Taste and smell disorders can worsen the nutritional status of patients receiving chemotherapy and potentially affect drug treatment. However, there is limited knowledge on antineoplastic agents that induce taste and smell disorders. Therefore, we used the U.S. Food and Drug Administration Adverse Event Reporting System database to analyze the characteristics of patients and antineoplastic agents in relation to taste and smell disorders. No gender differences related to the onset of taste and smell disorders were found, whereas older age was identified as a possible risk factor. Among the anti

Styles APA, Harvard, Vancouver, ISO, etc.

38

Mary Philip, Sherin, Joji Johnson, Litha Johnson, and Bharath Rangarajan. "A Review on Antineoplastic Agents Induced Toxicities and its Managements." International Journal of Science and Research (IJSR) 10, no. 8 (2021): 1005–12. https://doi.org/10.21275/sr21818165637.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

39

Chen, Rong. "A Pharmacovigilance Study of the Association between Antineoplastic Agents and Neutropenia Adverse Events Based on Food and Drug Administration Adverse Event Reporting System Data." Toxicology: Current Research 8, no. 1 (2024): 1–8. http://dx.doi.org/10.24966/tcr-3735/100029.

Texte intégral

Résumé :

Neutropenia is one of the most common adverse events associated with antineoplastic agents. However, comprehensive real-world studies on the relationship between antineoplastic agents and neutropenia are relatively scarce.

Styles APA, Harvard, Vancouver, ISO, etc.

40

Johnson, Candace S. "Modulation of chemotherapy antineoplastic agents with biologic agents." Current Opinion in Oncology 4, no. 6 (1992): 1108. http://dx.doi.org/10.1097/00001622-199212000-00016.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

41

Zhang, Hai-Long, and Yiqian Li. "Recent development of drugs for osteoporosis and anti-cancer agents: a patent analysis." Pharmaceutical Patent Analyst 10, no. 2 (2021): 73–82. http://dx.doi.org/10.4155/ppa-2021-0004.

Texte intégral

Résumé :

Osteoporosis and cancer are becoming a major public health problem. Some studies have shown that osteoporosis drugs may have anti-cancer effects. To better understand the relationship between drugs for osteoporosis and antineoplastic agents, and to better demonstrate recent developments for patents concerning drugs for osteoporosis, we conducted an analysis of US patents. The results indicated that there was a good correlation between agents for osteoporosis and antineoplastic agents, which indicated that numerous anti-osteoporosis agents displayed antineoplastic activities. Our study was the

Styles APA, Harvard, Vancouver, ISO, etc.

42

Beckwith, M. Christina, and Linda S. Tyler. "Preventing Medication Errors with Antineoplastic Agents, Part 1." Hospital Pharmacy 35, no. 5 (2000): 511–26. http://dx.doi.org/10.1177/001857870003500502.

Texte intégral

Résumé :

Goal — The goal of this program is to present practical ways to prevent medication errors with antineoplastic agents, identify common types of medication errors, and describe a system for reducing the incidence of medication errors and responding appropriately to antineoplastic medication errors. Objectives — At the completion of this program, the participant will be able to: 1. Describe the scope and impact of medication errors 2. Define common terms used in medication error literature. 3. List four common types of prescribing errors made with anti-neoplastic agents. 4. Identify steps where m

Styles APA, Harvard, Vancouver, ISO, etc.

43

Boschi, Rita, and Elena Rostagno. "Extravasation of antineoplastic agents: prevention and treatments." Pediatric Reports 4, no. 3 (2012): 28. http://dx.doi.org/10.4081/pr.2012.e28.

Texte intégral

Résumé :

The extravasation of antineoplastic agents is an unwanted and distressing situation that can easily occur. It may cause severe and irreversible local injuries. Left untreated, vesicant chemotherapy extravasation can potentially cause tissue necrosis, functional impairment and permanent disfigurement. This article provides a review of current literature regarding recommendations on the prevention and treatment of extravasation of antineoplastic agents.

Styles APA, Harvard, Vancouver, ISO, etc.

44

&NA;. "Antineoplastic agents can cause allergic reactions." Reactions Weekly &NA;, no. 428 (1992): 4. http://dx.doi.org/10.2165/00128415-199204280-00008.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

45

&NA;. "Pharmacokinetic drug interactions with antineoplastic agents." Drugs & Therapy Perspectives 5, no. 9 (1995): 12–14. http://dx.doi.org/10.2165/00042310-199505090-00005.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

46

BATRA, JANENDRA K., CHII M. LIN, ERNEST HAMEL, LEONARD JURD, and LARRY J. POWERS. "New Antineoplastic Agents with Antitubulin Activity." Annals of the New York Academy of Sciences 466, no. 1 Dynamic Aspec (1986): 785–87. http://dx.doi.org/10.1111/j.1749-6632.1986.tb38459.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

47

McDiarmid, Melissa, and Thomas Egan. "Acute Occupational Exposure to Antineoplastic Agents." Journal of Occupational and Environmental Medicine 30, no. 12 (1988): 984–87. http://dx.doi.org/10.1097/00043764-198812000-00020.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

48

Dimopoulou, I., A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos. "Pulmonary toxicity from novel antineoplastic agents." Annals of Oncology 17, no. 3 (2006): 372–79. http://dx.doi.org/10.1093/annonc/mdj057.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

49

Delitheos, A., I. Karavokyros, and E. Tiligada. "Response ofSaccharomyces cerevisiaestrains to antineoplastic agents." Journal of Applied Bacteriology 79, no. 4 (1995): 379–83. http://dx.doi.org/10.1111/j.1365-2672.1995.tb03151.x.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

50

Phillips, Nancy C. "The Safe Handling of Antineoplastic Agents." Journal of Pharmacy Technology 1, no. 1 (1985): 19–24. http://dx.doi.org/10.1177/875512258500100108.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!